Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. - Wikidata - wikimedia - TriplyDB

Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.

Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.

http://www.wikidata.org/entity/Q42905606

about

Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options Tigecycline : a critical safety review Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship.Antibiotics for ventilator-associated pneumonia.Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria.Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting.Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia Safety and efficacy of commonly used antimicrobial agents in the treatment of enterococcal infections: a review.Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia.Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA)Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.How to treat VAP due to MDR pathogens in ICU patients.Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline Carbapenemase-producing Enterobacteriaceae.Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics.Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex Excess deaths associated with tigecycline after approval based on noninferiority trials.Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection Continuous beta-lactam infusion in critically ill patients: the clinical evidence Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia.Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid Antibiotics for the critically ill: more than just selecting appropriate initial therapy.Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study.Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy.Efficacy and safety of tigecycline: a systematic review and meta-analysis.Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes.Revisiting "older" antimicrobials in the era of multidrug resistance.Pharmacokinetic and pharmacodynamic evaluation of tigecycline.Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.

P2860

Q24612271-6F2EAAAF-6458-411B-82B9-66E10367FE70 Q26853465-16A65EFE-1E41-4815-A4ED-7C7B628A1164 Q26991886-5CE138D4-42CF-495B-B174-7C06B5279558 Q27015109-0482B097-AD0E-4E8D-95A6-89E6079AC527 Q28254593-BF9D9539-0017-4C84-A9F0-FFFFA66F4454 Q28550492-B798620F-E66D-4825-BFD7-091BEFBA36D6 Q30238578-4442B161-D835-49C6-BFB8-A381AF98C137 Q30243877-A6C59E98-03D4-4FC0-891E-2EAE1FD30EA9 Q33732524-1A369AEE-6C1F-474F-8190-32D67266340E Q33754471-913D779A-8813-4229-8FB6-136B02AE27D1 Q33770721-D9AF7F4E-6F69-4041-9E70-67B8CECF02FB Q34309574-72A21273-2236-479B-8192-417FD339CC2A Q34414748-024360B5-7436-42A7-95B5-DC329C7DE281 Q34503844-96C6D41C-A7A0-4994-8F41-69F2956F5968 Q35026616-B0ACDBB7-FD85-49E4-A962-5523A39104A5 Q35117981-A7E52329-8BC3-4A42-B512-5DBD5D6E9404 Q35168955-8A5006EE-2361-45A9-B1FE-C3BF65382DD7 Q35457068-73686DF1-0619-4866-AB9E-6B30FEF35B02 Q35689185-E87C0F4E-F25D-43E3-BEE5-0DB23BCB0D4C Q35751615-B2A9F08B-8FCE-474E-9DFF-E8035491FBFF Q35806456-0D6A1F99-66E7-467F-993C-5BDA6E0D295C Q36078359-A3CEF7C3-7B9B-48D6-B9FE-1A7ADE5A0272 Q36096472-433FFCC0-1F63-4BFE-9BF0-47938ADAC7A3 Q36115632-3B12E091-6565-4255-BDFD-AE4EFB2D0061 Q36178130-5DA4D982-EE90-45FE-A658-03DDB3E27A59 Q36329228-71F30F41-E2CA-42B7-AD06-9C39294F9FC9 Q36438971-49884668-D51B-42ED-8E51-8CD2E9AEE89D Q36757628-A47BB395-E66F-401F-A297-732858115A16 Q36761826-215B1F29-1557-4F37-8D92-21EE4D857EC3 Q36902744-78097D75-25D2-4055-9F31-42EB3FA6A330 Q36924714-0B3631D9-FD26-4522-B4EB-952FF827EF27 Q36998603-55B7C52E-B2AC-4D4B-B512-8DC1BAF0A335 Q37377897-C6194696-8863-47EE-A24C-692DEF41755D Q37511815-85A09595-70D5-4A09-8808-619B6A27C238 Q37821604-5C91FDF3-B5FC-4DA3-9512-E3BFE5C53190 Q37891606-3DD2372B-D12B-415E-B8F4-BAD4D6F58F59 Q37894694-21A5ABBB-C117-4797-A6E6-9B28B0429FD8 Q37933412-D38E736F-F4E6-4C42-9C7D-3EC02E34CDC1 Q37940546-535211EB-7AE0-4381-AE57-17094FD91C56 Q37955286-759EE5BC-D286-49D5-98CC-B1FFDF9E9A48

P2860

Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.

http://www.wikidata.org/entity/Q42905606

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Comparison of tigecycline with ...... f hospital-acquired pneumonia.

@en

Comparison of tigecycline with ...... f hospital-acquired pneumonia.

@nl

type

label

Comparison of tigecycline with ...... f hospital-acquired pneumonia.

@en

Comparison of tigecycline with ...... f hospital-acquired pneumonia.

@nl

prefLabel

Comparison of tigecycline with ...... f hospital-acquired pneumonia.

@en

Comparison of tigecycline with ...... f hospital-acquired pneumonia.

@nl

P1433

Q42905606-ADDB9ACA-DA8C-467C-B6F6-38AC12AB7CE1

P1476

Q42905606-E58A5CB7-30F7-435F-BE7A-EB40D681F02E

P2093

Q42905606-33F3CE74-208A-468B-9A59-7239FD5C46BB

Q42905606-653B25CC-432B-4927-A9E8-A955233C8AF9

Q42905606-6C0D8C04-3D33-471C-9F24-F5A45A8E15C5

Q42905606-74282AA2-5652-420D-ADBB-694AD3A28C73

Q42905606-86BBD297-6851-44D1-9606-69E956DB6CA2

Q42905606-888AAEAD-7C7F-4C90-B101-F127CDD14F17

Q42905606-A5B9D47A-AD6B-4DF7-9712-E686DFA3AB0F

Q42905606-CC72D8B2-5F07-4594-A777-5AA2FF209889

Q42905606-DE57A98B-52CA-4822-86C5-D8E198D60D67

Q42905606-E422351E-B187-4094-8904-47F1876C8C92

P304

Q42905606-27079EC9-EF58-42D8-8C0B-958D97D23667

P31

Q42905606-AA4FFB57-C36B-429B-B7D1-26A1F12C9D69

P356

Q42905606-46782FA6-5C50-4CE4-9AE3-7CE6B08626A1

P433

Q42905606-6275D3DA-5BAB-4A1E-9625-9AF4EF500776

P478

Q42905606-ADF21A92-22A0-44A6-958F-10CAF6481BB2

P577

Q42905606-5DB74247-2A3F-459A-9623-1B8C34836DF9

P698

Q42905606-A6990A62-7088-47B1-9DA7-049604FAF128

P921

Q42905606-C3A929C4-39C1-4C6A-8BB1-6805318BF0EE

P356

J.DIAGMICROBIO.2010.05.012

P1433

Diagnostic Microbiology and Infectious Disease

P1476

Comparison of tigecycline with ...... f hospital-acquired pneumonia.

@en

P2093

311 Study Group

http://www.w3.org/2001/XMLSchema#string

Antonio T Freire

http://www.w3.org/2001/XMLSchema#string

C Angel Cooper

http://www.w3.org/2001/XMLSchema#string

Felix Glumcher

http://www.w3.org/2001/XMLSchema#string

Gary Dukart

http://www.w3.org/2001/XMLSchema#string

Hassan Gandjini

http://www.w3.org/2001/XMLSchema#string

Joan M Korth-Bradley

http://www.w3.org/2001/XMLSchema#string

Min Ja Kim

http://www.w3.org/2001/XMLSchema#string

Nathalie Dartois

http://www.w3.org/2001/XMLSchema#string

Oleksandr Dzyublik

http://www.w3.org/2001/XMLSchema#string

P304

140-151

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.DIAGMICROBIO.2010.05.012

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20846586

http://www.w3.org/2001/XMLSchema#string

P921